
MRSN
Mersana Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.040
Open
6.940
VWAP
--
Vol
142.30K
Mkt Cap
33.65M
Low
6.580
Amount
--
EV/EBITDA(TTM)
--
Total Shares
122.36M
EV
-47.24M
EV/OCF(TTM)
--
P/S(TTM)
25.20
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
6.70M
-59.04%
-0.454
+312.73%
6.15M
-51.19%
-0.904
+904.44%
6.06M
+164.16%
-0.170
-15%
Estimates Revision
The market is revising Downward the revenue expectations for Mersana Therapeutics, Inc. (MRSN) for FY2025, with the revenue forecasts being adjusted by -19.78% over the past three months. During the same period, the stock price has changed by -37.63%.
Revenue Estimates for FY2025
Revise Downward

-19.78%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-24.87%
In Past 3 Month
Stock Price
Go Down

-37.63%
In Past 3 Month
5 Analyst Rating

-55.56% Downside
Wall Street analysts forecast MRSN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRSN is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy

-55.56% Downside
Current: 6.750

Low
3.00
Averages
3.00
High
3.00

-55.56% Downside
Current: 6.750

Low
3.00
Averages
3.00
High
3.00
Truist
Buy
maintain
$9 -> $10
2025-05-16
Reason
Truist
Price Target
$9 -> $10
2025-05-16
maintain
Buy
Reason
Truist raised the firm's price target on Mersana Therapeutics to $10 from $9 and keeps a Buy rating on the shares after its Q1 results. The firm is positive on the company's Emi-Le's improving overall response ratio in B7-H7 high patients as well as Mersana beening able to push the dose higher with prophylactic tox management and step dosing, the analyst tells investors in a research note.
William Blair
Andy Hsieh
Buy
Initiates
n/a
2025-02-06
Reason
William Blair
Andy Hsieh
Price Target
n/a
2025-02-06
Initiates
Buy
Reason
Citigroup
Ashiq Mubarack
Strong Buy
Maintains
$6 → $5
2024-08-27
Reason
Citigroup
Ashiq Mubarack
Price Target
$6 → $5
2024-08-27
Maintains
Strong Buy
Reason
Baird
Colleen Kusy
Hold
Maintains
$4 → $3
2024-08-14
Reason
Baird
Colleen Kusy
Price Target
$4 → $3
2024-08-14
Maintains
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Mersana Therapeutics Inc (MRSN.O) is -0.16, compared to its 5-year average forward P/E of -4.53. For a more detailed relative valuation and DCF analysis to assess Mersana Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-4.53
Current PE
-0.16
Overvalued PE
-0.37
Undervalued PE
-8.68
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-2.88
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.76
Undervalued EV/EBITDA
-6.52
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
2241.88
Current PS
1.53
Overvalued PS
11076.50
Undervalued PS
-6592.73
Financials
Annual
Quarterly
FY2025Q1
YoY :
-70.21%
2.75M
Total Revenue
FY2025Q1
YoY :
+16.72%
-24.51M
Operating Profit
FY2025Q1
YoY :
+24.95%
-24.12M
Net Income after Tax
FY2025Q1
YoY :
+18.75%
-0.19
EPS - Diluted
FY2025Q1
YoY :
-10.56%
-29.33M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
-48.84%
-232.34
FCF Margin - %
FY2025Q1
YoY :
+319.45%
-875.93
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
51.3K
USD
18
0-12
Months
217.2K
USD
12
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
6.7M
Volume
1
6-9
Months
9.1M
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
6.9M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
51.3K
USD
18
0-12
Months
217.2K
USD
12
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MRSN News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
08:42:21
Mersana Therapeutics announces 1-for-25 reverse stock split

2025-06-02 (ET)
2025-06-02
08:38:10
Mersana Therapeutics reports additional interim Phase 1 data for Emi-Le

2025-05-15 (ET)
2025-05-15
07:10:31
Mersana Therapeutics reports Q1 EPS (19c), consensus (19c)

Sign Up For More Events
Sign Up For More Events
News
2.0
07-27TipRanksUpcoming Stock Splits This Week (July 28 to August 1) – Stay Invested
7.0
07-24NASDAQ.COMMersana To Implement 1-for-25 Reverse Stock Split To Regain Nasdaq Compliance
2.0
07-24NewsfilterMersana Therapeutics Announces 1-for-25 Reverse Stock Split
Sign Up For More News
People Also Watch

BNR
Burning Rock Biotech Ltd
6.470
USD
+11.36%

OPTX
Syntec Optics Holdings Inc
2.090
USD
+10.58%

HYPR
Hyperfine Inc
1.020
USD
-2.86%

NSPR
InspireMD Inc
2.370
USD
-2.87%

LSF
Laird Superfood Inc
7.000
USD
0.00%

PMVP
PMV Pharmaceuticals Inc
1.420
USD
-1.39%

FUSB
First US Bancshares Inc
13.200
USD
+2.80%

CLSD
Clearside Biomedical Inc
0.450
USD
-6.25%

VANI
Vivani Medical Inc
1.430
USD
-4.67%
FAQ

What is Mersana Therapeutics Inc (MRSN) stock price today?
The current price of MRSN is 6.75 USD — it has decreased -2.88 % in the last trading day.

What is Mersana Therapeutics Inc (MRSN)'s business?

What is the price predicton of MRSN Stock?

What is Mersana Therapeutics Inc (MRSN)'s revenue for the last quarter?

What is Mersana Therapeutics Inc (MRSN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Mersana Therapeutics Inc (MRSN)'s fundamentals?

How many employees does Mersana Therapeutics Inc (MRSN). have?
